More HHS upheaval, 23andMe’s bankruptcy, and AI for cancer survival

Can an AI tool be better than the industry standard at predicting which cancer patients will respond to treatment? Will drug companies feel the impacts of new cuts at the Department of Health and Human Services? And what will happen to all of the consumer health data owned by 23andMe?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. Adam, Elaine, and Allison discuss the Trump administration’s plan for huge job cuts and a restructuring of the country’s top health care agencies, the approval of the first drug to treat a devastating rare disease, and the bankruptcy of 23andMe.

Read the rest…